# Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders

_Wednesday, July 22, 2026 at 8:00 AM EDT · AI · Latest · Tier 2 — Notable_

![Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders — Primary](https://static.tildacdn.com/tild6635-6464-4665-a565-343266373762/f45686ca449c58cd7f19.jpg)

**Implication:** Pharmaceutical companies are structuring large milestone-based deals with AI drug discovery firms, as Insilico Medicine's agreement with SK Biopharmaceuticals shows.

Insilico Medicine and SK Biopharmaceuticals announced a research and development collaboration at the BIO 2026 International Convention to discover AI-enabled innovative drug candidates in the neuroimmune area of the central nervous system. Under the agreement, Insilico will be eligible to receive up to $18 million in upfront and near-term milestone payments. The total potential deal value exceeds $2.5 billion, including development, regulatory, and commercial milestone payments, as well as single-digit royalties on net sales upon commercialization.

## Sources

- [insilico.com](https://insilico.com/news/zm8me18st1-insilico-medicine-and-sk-biopharmaceutic)

---
Canonical: https://techandbusiness.org/newswire/rToyVRV_hr_TKQIINBNegJ
Retrieved: 2026-07-22T12:59:00.020Z
Publisher: Tech & Business (techandbusiness.org)